AI Article Synopsis
- Statins are the main medication used to lower LDL cholesterol and have been shown to decrease inflammatory markers.
- Ezetimibe, when added to statin therapy, also lowers LDL cholesterol and decreases cardiovascular events, but its effect on inflammation is less understood.
- A recent study suggests that ezetimibe does reduce inflammation alongside statins, though there is limited data on specific inflammatory markers like CRP, TNFα, and IL-6.
Article Abstract
Statins are the primary pharmacological intervention to reduce LDL cholesterol; they significantly reduce inflammatory markers. Ezetimibe also reduces LDL cholesterol and reduces cardiovascular events when given on top of statin therapy. Whether ezetimibe, like statins, reduces markers of inflammation is less clear. We, therefore, conducted a systematic literature research addressing the impact of ezetimibe on CRP, TNFα and IL-6 when given on top of statin therapy. Our work indicates that overall ezetimibe reduces inflammation on top of statin treatment. However, available data are limited for CRP and even more so for TNFα and IL-6.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10787-023-01209-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Type 2 diabetes genetic risk and incident diabetes across diabetes risk enhancers.
Diabetes Obes Metab
December 2024
TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Aims: To evaluate the predictive value of a contemporary type 2 diabetes (T2D) polygenic score (PGS) in detecting incident diabetes across a range of diabetes risk factors.
Materials And Methods: We analysed participants in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial (ClinicalTrials.gov, number NCT0176463), which compared the efficacy of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab versus placebo in lowering cardiovascular outcomes in participants with stable atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg/dL (1.
The Diabetogenic Effect of Statin Use May Interact With Polygenic Risk Scores for Type 2 Diabetes.
J Prev Med Public Health
December 2024
Graduate School of Public Health, Seoul National University, Seoul, Korea.
Article Synopsis
- - The study explored how genetic susceptibility to type 2 diabetes (T2DM) affects the risk associated with regular statin use in preventing cardiovascular disease among 447,176 individuals.
- - Results showed that statin users in the highest polygenic risk score (PRS) group had a higher incidence of T2DM (15.42 cases per 1,000 person-years) compared to non-users (12.18), while those in the lowest group had similar low rates.
- - Findings suggest that PRS can help identify individuals at greater risk for developing T2DM from statin use, which could lead to more personalized treatment strategies for managing cardiovascular health.
Top 10 Tips for Using Statins in Clinical Practice.
Mayo Clin Proc
December 2024
Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Medicine, Division of Cardiology, Northwestern University, Chicago, IL.
Statins are the mainstay of cholesterol treatment to prevent atherosclerotic cardiovascular disease. However, significant barriers, including physician and patient factors, prevent the optimal use of this drug class. In this article, we provide 10 clear and simple tips for clinicians when prescribing statins.
View Article and Find Full Text PDFQSAR Regression Models for Predicting HMG-CoA Reductase Inhibition.
Pharmaceuticals (Basel)
October 2024
Department of Pharmaceutical Botany and Cell Biology, Faculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Background/objectives: HMG-CoA reductase is an enzyme that regulates the initial stage of cholesterol synthesis, and its inhibitors are widely used in the treatment of cardiovascular diseases.
Methods: We have created a set of quantitative structure-activity relationship (QSAR) models for human HMG-CoA reductase inhibitors using nested cross-validation as the primary validation method. To develop the QSAR models, we employed various machine learning regression algorithms, feature selection methods, and fingerprints or descriptor datasets.
Machine learning models for predicting risks of MACEs for myocardial infarction patients with different VEGFR2 genotypes.
Front Med (Lausanne)
September 2024
Faculty of Computer Science, AI and Digital Science Institute, International Laboratory of Bioinformatics, Higher School of Economics University, Moscow, Russia.
Article Synopsis
- The study develops a machine learning model to predict major adverse cardiac events (MACEs) in high-risk myocardial infarction (MI) patients, incorporating clinical, imaging, laboratory, and genetic data.
- It analyzes data from 218 MI patients over 9 years, focusing on the influence of the VEGFR-2 gene variant as part of the overall risk assessment.
- The CatBoost algorithm performed best, with statin dosage and genetic factors identified as key predictors of adverse events, highlighting the potential for personalized treatment approaches based on genetic information.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!